LEO Pharma acquires Timber Pharmaceutical’s bankruptcy assets including TMB-001

Following the bankruptcy of Timber Pharmaceuticals, LEO Pharma has finalized the acquisition of TMB-001 and other assets from Timber, according to a press release.
In November 2023, Timber Pharmaceuticals filed for chapter 11 bankruptcy. Since then, LEO Pharma has acquired the strategic asset TMB-001, an investigational topical reformulation isotretinoin that has received orphan, fast track and breakthrough designation from the FDA.
LEO Pharma intends to continue developing the drug for the treatment of multiple moderate to severe subtypes of congenital ichthyosis, a condition which currently

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart